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shedding Light on Proteolytic 
Cleavage of CD44:  
The Responsible sheddase and 
Functional significance of shedding
Ivan Stamenkovic1 and Qin Yu2
CD44 is the major cell-surface receptor for hyaluronan, which is implicated 
in cell–cell and cell–matrix adhesion, cell migration, and signaling. studies 
have shown that CD44-dependent migration requires CD44 to be shed from 
the cell surface and that matrix metalloproteinase–mediated cleavage may 
provide an underlying mechanism. However, the full spectrum of proteases 
that may participate in CD44 shedding has yet to be defined. In this issue, 
Anderegg et al. demonstrate that ADAM10, but not ADAM17 or MMP14, 
mediates constitutive shedding of CD44 in human melanoma cells and that 
knockdown of ADAM10 blocks the antiproliferative activity of the soluble 
proteolytic cleavage product of CD44.
Journal of Investigative Dermatology (2009) 129, 1321–1324. doi:10.1038/jid.2009.13
roles of cD44 and aDam10 
in melanoma progression
Studies have suggested an important 
role for CD44 in melanoma growth and 
progression. Thus, increased expression 
of CD44 and CD44–hyaluronan (HA) 
interaction correlate, respectively, with 
melanoma progression and metastatic 
proclivity of melanoma cells (De Wit et 
al., 1996). CD44 mediates HA-induced 
melanoma cell proliferation (Ahrens et 
al., 2001a), and CD44–HA interaction is 
required for melanoma development in 
mouse models (Bartolazzi et al., 1994). 
Functional blocking anti-CD44 antibody 
inhibits growth and metastasis of human 
melanoma cells (Guo et al., 1994), and 
soluble CD44 inhibits melanoma tumor 
growth by blocking HA binding to cell-
surface CD44 (Ahrens et al., 2001b). 
In addition, hepatocyte growth fac-
tor engagement of its receptor, c-Met, 
upregulates expression of CD44v6 in 
murine melanoma cells (Recio and 
Merlino, 2003), and HA-mediated inter-
action between CD44 and epidermal 
growth factor receptor promotes mela-
noma cell motility by activating protein 
kinase C signaling (Kim et al., 2008).
ADAM (a disintegrin and metallo-
proteinase) is a family of cell-surface 
proteases that are related to matrix 
metal loproteinases (MMPs) and contain 
several defined functional domains, 
including metalloproteinase, disinteg-
rin, cysteine-rich, and transmembrane 
domains, as well as a cytoplasmic tail. 
ADAMs serve as the major class of shed-
dases for many important cell-surface 
receptors, and they play an essential 
role in regulating interactions between 
tumor cells and their microenvironment 
and in initiating the activation of key 
signaling pathways. Expression levels 
of many ADAM family members are 
elevated in human cancers, and stud-
ies have suggested important roles for 
ADAMs in cancer growth and pro-
gression (reviewed by Mochizuki 
and Okada, 2007). Currently, little is 
known about the role of ADAM10 and 
the other ADAM family members in 
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melanoma initiation and progression. 
However, ADAM15 inhibits B16F10 
pulmonary metastasis, and the disin-
tegrin domain of ADAM15 displays an 
antiproliferative effect on melanoma 
cells (Murphy, 2008). Additional stud-
ies are required to determine the level 
of functional involvement of ADAM 
family proteases in the pathogenesis of 
human melanoma.
cD44 shedding and soluble cD44
Shedding of cell-surface adhesion 
receptors plays an important role in 
modulating cell–cell and cell–matrix 
adhesion, as well as in signaling initi-
ated by interactions of adhesion recep-
tors and their ligands in the microenvi-
ronment. CD44 shedding is observed 
in a variety of human tumors in vivo 
(Okamoto et al., 2002). Elevated sol-
uble CD44 (solCD44) levels in serum 
correlate with tumor burden and meta-
static potential of gastric and colon can-
cer, as well as unfavorable outcomes in 
non-Hodgkin’s lymphoma (reviewed 
by Nagano and Saya, 2004). In addi-
tion, increased levels of soluble CD44 
variant v6 (solCD44v6) are associated 
with increased tumor size, lymph node 
metastasis (Mayer et al., 2008), and 
resistance to chemotherapy (Kopp et 
al., 2001) in breast cancer patients.
CD44 shedding is triggered and 
regulated by multiple signaling path-
ways, including activation of protein 
kinase C, Ca2+ influx, and activity of 
small GTPases, including that of Ras 
(reviewed by Nagano and Saya, 2004). 
Epidermal growth factor and heregulin 
can induce CD44 shedding, whereas 
blocking the activity of ErbB-2 by tras-
tuzumab inhibits shedding (Pályi-Krekk 
et al., 2008), which may contribute to 
the mechanisms underlying the antitu-
mor efficacy of monoclonal antibodies 
that target ErbB receptor tyrosine kinas-
es. In addition, oligosaccharides of HA 
and chondroitin sulfate E trigger shed-
ding of CD44 from the tumor-cell sur-
face through the activity of unidentified 
proteases (Sugahara et al., 2008).
CD44 is composed of an extracel-
lular (ecto-) domain that contains an 
HA-binding cartilage link protein–
related domain and a membrane-prox-
imal region, a transmembrane domain, 
and a COOH-terminal cytoplasmic tail. 
The cytoplasmic tail interacts with a 
number of cytoskeletal proteins, includ-
ing the Band 4.1 superfamily members: 
the ezrin-radixin-moesin family pro-
teins and merlin. CD44 is sequentially 
cleaved proteolytically, first within 
the ectodomain, which results in the 
formation of a soluble extracellular 
fragment of CD44 (solCD44), and 
then within the intracellular domain 
(ICD), which produces an intracellular 
fragment (CD44ICD). CD44ICD can 
translocate into the nucleus to regulate 
transcription of target genes, including 
CD44 itself, which provides a positive 
feedback regulatory mechanism for 
CD44 expression (Nagano and Saya, 
2004). CD44 shedding is thought to be 
a functionally important process that 
triggers signaling pathways and regu-
lates CD44-mediated functions.
Cleavage of the ICD of CD44 is 
mediated by presenilin-dependent 
γ-secretase, whereas the shedding 
of CD44 is mediated by membrane-
associated metalloproteases, including 
membrane type 1 MMP (MT1-MMP 
or MMP14), ADAM10, and ADAM17 
(Nagano and Saya, 2004). CD44 shed-
ding is thought to result in enhanced 
cell motility. This notion is supported 
by the observation that migration of 
highly aggressive melanoma cells on 
HA is associated with increased shed-
ding and turnover of CD44 (Goebeler 
et al., 1996). However, the exact iden-
tity of the sheddase of CD44 in different 
cell types has not yet been established. 
Anderegg et al. (2009, this issue) show 
that although ADAM10, ADAM17, 
and MMP14 are expressed in human 
melanoma biopsies and CD44-positive 
human melanoma cells, ADAM10, but 
not MMP14 or ADAM17, is involved 
in constitutive shedding of CD44 from 
melanoma cells. In addition, Anderegg 
et al. show that inhibition of CD44 
shedding and the corresponding gen-
eration of solCD44 by ADAM10 knock-
down augments HA-induced prolif-
eration of melanoma cells in a CD44-
dependent manner.
It is important to distinguish between 
solCD44 generated through proteolytic 
shedding, which results in a fragment 
presumably lacking the binding domains 
for its sheddases, and recombinant solu-
ble CD44 generated through molecu-
lar cloning, which includes the entire 
extracellular domain (referred to hereaf-
ter as CD44ECD) that should contain the 
binding domains for its sheddases and 
ligands. CD44ECD may therefore serve as 
a dominant negative regulator of CD44 
shedding and interactions between cell-
surface CD44 and its ligands. Studies 
have consistently shown that CD44ECD 
and CD44ECD–Fc fusion proteins antago-
nize CD44 receptor function and display 
potent antitumor activity (Bartolazzi et 
al., 1994; Yu and Stamenkovic, 2000). 
On the other hand, elevated levels of 
solCD44 in patient serum correlate with 
tumor burden, metastatic pote ntial, 
and resistance to chemotherapy (Kopp 
et al., 2001; Nagano and Saya, 2004; 
Mayer et al., 2008). A potentially attrac-
tive view is that the solCD44 level is a 
surrogate marker for the intracellular 
level of CD44ICD and that CD44ICD exerts 
protumor activity, whereas solCD44 is a 
by-product of the proteo lytic cleavage of 
CD44 that may primarily regulate CD44-
dependent cell-surface interactions. 
Additional studies are required to fully 
understand whether and how CD44ICD 
activates signaling pathways that impact 
tumorigenesis and tumor progression 
and/or serve as a transcriptional cofac-
tor that regulates the expression of rel-
evant target genes. The identification of 
ADAM10 as the sheddase of CD44 in 
human melanoma cells by Anderegg et 
al. (2009) may help in the development 
of target-based anticancer therapy aimed 
at modulating CD44 shedding.
cD44 and cancer stem cells
There is increasing evidence to sug-
gest the existence of a small popula-
tion of specialized cancer cells that 
display stem-cell properties, commonly 
referred to as cancer stem cells (CSCs) 
or cancer initiating cells. CSCs are char-
acterized by their ability to self-renew, 
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differentiate into various lineages, and 
reconstitute the cellular hierarchy of the 
tumor from which they are derived in 
serial xenotransplant assays. These cells 
are highly resistant to chemo- and radio-
therapy and are believed to be responsi-
ble for tumor recurrence following ther-
apeutic intervention (Reya et al., 2001). 
CD44 has been identified as one of the 
most consistent markers of CSCs from a 
variety of malignancies, including leu-
kemia, breast, colon, ovarian, prostate, 
pancreatic, and head and neck cancers 
(Reya et al., 2001; Croker and Allan, 
2008). Thus, CD44+ CD24–/low breast 
cancer cells display CSC characteristics, 
with as few as 100 being able to form 
tumors in nude mice, whereas a hun-
dred- to a thousand-fold more CD44– 
cells fail to do so (Al-Hajj et al., 2003). 
Similarly, a CD44+/CD24+/ESA+/CD133+ 
population of pancreatic cancer cells 
has been shown to be highly tumori-
genic; CD44+/CD117+ ovarian cancer–
initiating cells overexpress ABCG2 and 
are more resistant to cisplatin and pacli-
taxel than their CD44– counterparts, 
and CD44+ cells of squamous cell car-
cinoma of the head and neck display 
CSC-like characteristics, including the 
expression of higher levels of genes 
related to chemoresistance compared 
with CD44– cells. Furthermore, CD44 
has been shown to play an essential 
role in engraftment of leukemia stem/
initiating cells in the bone marrow, an 
event that is a key precursor to leukemia 
development (see review by Croker and 
Allan, 2008). A recent study showed 
that CD44 is also functionally impor-
tant for colorectal cancer stem cells 
(Du et al., 2008). Together, these results 
indicate a potentially important role for 
CD44 in the formation, maintenance, 
and/or function of CSCs.
Perspectives and future directions
The recent definition of CSCs and the 
suggestion that they may play a central 
role in tumor development and resis-
tance to anticancer therapies require the 
identification of selective markers that 
could be used as therapeutic targets. 
Expression of CD44 by CSCs of a vari-
ety of malignancies and evidence that 
CD44 may play a functionally relevant 
role in the maintenance of these cells 
warrant investigation of targeting CD44 
as a means of inhibiting tumor forma-
tion, progression, and relapse. Given 
that CD44 shedding correlates with 
tumor burden and progression, a bet-
ter understanding of the underlying 
molecular and biochemical basis of the 
shedding may lead to the development 
of novel strategies and more effective 
therapeutic agents that target the bulk of 
cancer cells and CSCs.
There are many unanswered ques-
tions related to CD44 shedding. Does 
ADAM10 serve as the major sheddase 
of CD44 in other cancer types? If not, 
which other ADAMs might play this 
role? How is CD44 shedding regulated, 
and which domains of CD44 are respon-
sible for binding to the sheddases? What 
is the molecular basis for distinguishing 
constitutive from induced shedding of 
CD44? Is CD44 shed in CSCs, and what 
might be the functional consequence 
of CD44 shedding in these cells? How 
do the products of CD44 shedding—
solCD44 and CD44ICD—contribute 
to tumor progression and initiation/
maintenance of CSCs? What are the 
mechanisms underlying the functions 
of solCD44 and CD44ICD? Answers to 
these questions will set the foundation 
for future CD44-based therapeutic inter-
ventions in cancer.
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neuroendocrine Perspectives  
in Alopecia Areata:  
Does stress Play a Role?
Ralf Paus1,2 and Petra Arck3
Until recently, the popular notion that psychoemotional stress can have an 
impact on hair growth has been treated with skepticism and assigned to the 
realm of folklore by many authorities. Yet it has long been appreciated that epi-
sodes of alopecia areata (AA) have occurred after severely stressful life events 
(Reinhold, 1960; Whitlock, 1976). This has triggered debates about whether AA 
should be considered a psychosomatic disorder (Misery and Rousset, 2001; 
Willemsen et al., 2009).
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A convincing cause–effect relation-
ship has never been firmly established 
between perceived stress and AA onset, 
course, and/or severity. It is by no means 
trivial to reliably distinguish “stress” as 
a genuine disease trigger from disease-
induced distress that, retrospectively and 
erroneously, may be identified by affect-
ed individuals as the “cause” of their 
hair loss (Whitlock, 1976; Hadshiew et 
al., 2004). In fact, the concept that AA 
can be triggered by psychoemotional 
stress has been cast into doubt (van der 
Steen et al., 1992; Brajac et al., 2003). 
With the increasing evidence that AA is 
a T-cell-dependent, organ-specific auto-
immune disease, the genesis of which is 
a collapse of the hair follicle’s immune 
privilege (Paus et al., 2005, Gilhar et 
al., 2007), the “brain–skin connection” 
(Paus et al., 2006) has been neglected.
However, the fact remains that cases 
have been reported—albeit rarely—
in which psychoemotional stress has 
clearly preceded AA onset or relapse, 
perhaps most impressively in the form 
of alopecia à deux in a husband-and-
wife setting under conditions of shared 
emotional stress (Swift, 1961; Zalka et 
al., 1994). Moreover, striking abnor-
malities in peptidergic innervation of 
lesional hair follicles have been iden-
tified in AA (Hordinsky and Ericson, 
1996). The expression of receptors for 
a key neuroendocrine stress mediator, 
corticotropin-releasing hormone, and 
of another classic mediator along the 
hypothalamic–pituitary–adrenal (HPA) 
stress-response axis, adrenocorticotro-
pin, were reported to be upregulated in 
lesional hair follicles of small cohorts of 
patients (Katsarou-Katsari et al., 2001; 
Kim et al., 2006).
This ambiguous picture makes it 
inevitable that investigators will turn to 
animal models for help. Indeed, it was 
in mice that the first solid evidence was 
at long last generated that perceived 
stress could exert surprisingly profound 
hair growth–inhibitory effects, includ-
ing the premature induction of hair fol-
licle regression (catagen), probably as 
a consequence of perifollicular neuro-
genic inflammation (Arck et al., 2001, 
2003; Aoki et al., 2003; Katayama et al., 
2007). Subsequently, detailed work in 
mice has identified at least one plausible 
molecular stress-response pathway by 
which perceived stress can lead to hair 
growth inhibition, with key roles identi-
fied for nerve growth factor, substance P 
(SP) and the cognate receptors as central 
stress mediators, and mast cells as “cen-
tral switchboards” of stress-induced 
perifollicular neurogenic inflammation 
(Arck et al., 2005; Peters et al., 2006).
This body of work has established 
that psychoemotional stress can indeed 
negatively impact hair growth, at least 
in mice. What has not been resolved, 
however, are the following questions: 
(i) whether any of this is relevant for 
humans, (ii) whether perceived stress 
can also induce actual hair shaft shed-
ding, leading to visible alopecia, in 
mice, and (iii) whether stress can trigger 
or aggravate AA (in mice or in humans). 
The recent observations that both nerve 
growth factor and SP are potent hair 
growth inhibitors for human hair and 
that SP causes the major histocompat-
ibility complex class I–based immune 
privilege of the hair follicle to collapse 
(Peters et al., 2005, 2007) suggest that 
the stress studies for mice summarized 
above are relevant to humans as well. 
However, convincing experimental 
evidence that AA—or any form of vis-
ible hair loss, for that matter—can be 
triggered by perceived stress remains 
to be published.
It is in this area that the study by Zhang 
and co-workers (2009, this issue) attains 
special relevance and importance—not 
only by adding a long-overdue facet to 
our incomplete understanding of AA 
pathogenesis but also for its bearing on 
general stress research and cutaneous 
neuroendocrinology.
Given that psychoemotional 
contributions to AA in humans may be 
camouflaged by emotional responses to 
the hair loss itself, the authors elegantly 
aimed at teasing apart stress-response 
